Roger Dilts, PhD, has extensive experience working as an educator, researcher, and consultant. During his doctoral thesis, Dr. Dilts was one of the first to correctly identify the localization of opioid receptors to non-dopaminergic neurons within brain reward pathways. Following this discovery, he went on to be one of the first to identify and characterize the expression of immediate early gene proteins, such as Fos, within the dopaminergic systems of the brain.
Significantly, while at Amylin Pharmaceuticals, he worked on the discovery and development of two new drugs for Diabetes mellitus, Symlin and Byetta. As an educator, Dr. Dilts has focused his attention on student success and increased diversity, including creating the first four year Life Science degree program within a Tribal college (“TCU”, a White House initiative on American Indian and Alaska Native education), the first molecular genetics laboratory within a Tribal college, and assisting students with Scotopic sensitivity, as well as many other study skills and methodologies.
Dr. Dilts’ current interests are many but include; medical education, the importance of diet and exercise in regulating metabolism and preventing disease, as well as drug discovery and innovations in the treatment of obesity and Diabetes mellitus.